Figure 1 shows that moderate‐to‐severe asthma patients who did not respond well to omalizumab have a higher mRNA expression of 4 out of 5 identified genes when compared to responders: LOC100131780, CCDC113, SLC26A and PPP1R3D. The gene discussed is CFAP263; the disease is asthma.